208 related articles for article (PubMed ID: 17668369)
1. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS.
Meanwell NA; Kadow JF
Curr Opin Investig Drugs; 2007 Aug; 8(8):669-81. PubMed ID: 17668369
[TBL] [Abstract][Full Text] [Related]
2. Treatment of HIV infection with the CCR5 antagonist maraviroc.
Kromdijk W; Huitema AD; Mulder JW
Expert Opin Pharmacother; 2010 May; 11(7):1215-23. PubMed ID: 20402558
[TBL] [Abstract][Full Text] [Related]
3. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M
Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317
[TBL] [Abstract][Full Text] [Related]
4. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.
Emmelkamp JM; Rockstroh JK
Eur J Med Res; 2007 Oct; 12(9):409-17. PubMed ID: 17933722
[TBL] [Abstract][Full Text] [Related]
5. A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc.
Rosario MC; Jacqmin P; Dorr P; van der Ryst E; Hitchcock C
Clin Pharmacol Ther; 2005 Nov; 78(5):508-19. PubMed ID: 16321617
[TBL] [Abstract][Full Text] [Related]
6. How will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV-1 infection.
van Lunzen J
Eur J Med Res; 2007 Oct; 12(9):435-40. PubMed ID: 17933725
[TBL] [Abstract][Full Text] [Related]
7. CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1.
Bredeek UF; Harbour MJ
Eur J Med Res; 2007 Oct; 12(9):427-34. PubMed ID: 17933724
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.
Fätkenheuer G; Pozniak AL; Johnson MA; Plettenberg A; Staszewski S; Hoepelman AI; Saag MS; Goebel FD; Rockstroh JK; Dezube BJ; Jenkins TM; Medhurst C; Sullivan JF; Ridgway C; Abel S; James IT; Youle M; van der Ryst E
Nat Med; 2005 Nov; 11(11):1170-2. PubMed ID: 16205738
[TBL] [Abstract][Full Text] [Related]
9. Maraviroc: a new CCR5 antagonist.
Sayana S; Khanlou H
Expert Rev Anti Infect Ther; 2009 Feb; 7(1):9-19. PubMed ID: 19622053
[TBL] [Abstract][Full Text] [Related]
10. [CCR5 antagonist Maraviroc: effective and well tolerated. "A very promising substance"].
Zorn F
MMW Fortschr Med; 2011 May; 153(18):30-1. PubMed ID: 21604590
[No Abstract] [Full Text] [Related]
11. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
Lieberman-Blum SS; Fung HB; Bandres JC
Clin Ther; 2008 Jul; 30(7):1228-50. PubMed ID: 18691983
[TBL] [Abstract][Full Text] [Related]
12. Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
Prescrire Int; 2008 Jun; 17(95):98-101. PubMed ID: 18623908
[TBL] [Abstract][Full Text] [Related]
13. Drug safety evaluation of maraviroc for the treatment of HIV infection.
Wasmuth JC; Rockstroh JK; Hardy WD
Expert Opin Drug Saf; 2012 Jan; 11(1):161-74. PubMed ID: 22118500
[TBL] [Abstract][Full Text] [Related]
14. Maraviroc.
Carter NJ; Keating GM
Drugs; 2007; 67(15):2277-88; discussion 2289-90. PubMed ID: 17927288
[TBL] [Abstract][Full Text] [Related]
15. CCR5 antagonists in the treatment of treatment-experienced patients infected with CCR5 tropic HIV-1.
Lorenzen T; Stoehr A; Walther I; Plettenberg A
Eur J Med Res; 2007 Oct; 12(9):419-25. PubMed ID: 17933723
[TBL] [Abstract][Full Text] [Related]
16. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents.
MacArthur RD; Novak RM
Clin Infect Dis; 2008 Jul; 47(2):236-41. PubMed ID: 18532888
[TBL] [Abstract][Full Text] [Related]
17. When and how to use maraviroc in HIV-infected patients.
Soriano V; Perno CF; Kaiser R; Calvez V; Gatell JM; di Perri G; Pillay D; Rockstroh J; Geretti AM
AIDS; 2009 Nov; 23(18):2377-85. PubMed ID: 19834318
[No Abstract] [Full Text] [Related]
18. [CCR5 antagonists: a new class of antiretrovirals].
Peytavin G; Calvez V; Katlama C
Therapie; 2009; 64(1):9-16. PubMed ID: 19463248
[TBL] [Abstract][Full Text] [Related]
19. CCR5 pharmacology methodologies and associated applications.
Mansfield R; Able S; Griffin P; Irvine B; James I; Macartney M; Miller K; Mills J; Napier C; Navratilova I; Perros M; Rickett G; Root H; van der Ryst E; Westby M; Dorr P
Methods Enzymol; 2009; 460():17-55. PubMed ID: 19446719
[TBL] [Abstract][Full Text] [Related]
20. Clinical studies with chemokine receptor-5 (CCR5)-inhibitors.
Boesecke C; Pett SL
Curr Opin HIV AIDS; 2012 Sep; 7(5):456-62. PubMed ID: 22832708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
